Supplementary Figure 1A from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Progression-free survival by subgroup in (A) cohort 1 and (B) cohort 2 HR based on unstratified Cox regression model with <1 favoring enzalutamide arm. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio.